MAZE THERAPEUTICS, INC. Increase Decrease In Operating Lease Liability
MAZE THERAPEUTICS, INC. (MAZE) reported Increase Decrease In Operating Lease Liability of -$1.84 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-11
- MAZE THERAPEUTICS, INC. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$928.00K.
- MAZE THERAPEUTICS, INC. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$915.00K.
- MAZE THERAPEUTICS, INC. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$879.00K.
- MAZE THERAPEUTICS, INC. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$825.00K.
- MAZE THERAPEUTICS, INC. increase decrease in operating lease liability for fiscal 2025 was -$3.32M.
- MAZE THERAPEUTICS, INC. increase decrease in operating lease liability for fiscal 2024 was -$2.92M.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$928.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$1.84M 10-Q · filed 2026-08-11 | -$2.72M derived: sum of 3 quarters · filed 2026-08-11 | -$3.55M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$915.00K 10-Q · filed 2026-05-12 | -$1.79M derived: sum of 2 quarters · filed 2026-05-12 | -$2.62M derived: sum of 3 quarters · filed 2026-05-12 | -$3.43M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$879.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | -$1.70M derived: sum of 2 quarters · filed 2026-03-25 | -$2.52M derived: sum of 3 quarters · filed 2026-08-11 | -$3.32M 10-K · filed 2026-03-25 |
| 2025-09-30 | -$825.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$1.64M derived: sum of 2 quarters · filed 2026-08-11 | -$2.44M 10-Q · filed 2025-11-06 | -$3.23M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$815.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$1.62M 10-Q · filed 2026-08-11 | -$2.40M derived: sum of 3 quarters · filed 2026-08-11 | -$3.12M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$805.00K 10-Q · filed 2026-05-12 | -$1.59M derived: sum of 2 quarters · filed 2026-05-12 | -$2.31M derived: sum of 3 quarters · filed 2026-05-12 | -$3.02M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$784.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | -$1.50M derived: sum of 2 quarters · filed 2026-03-25 | -$2.22M derived: sum of 3 quarters · filed 2026-03-25 | -$2.92M 10-K · filed 2026-03-25 |
| 2024-09-30 | -$720.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$1.43M derived: sum of 2 quarters · filed 2025-11-06 | -$2.13M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | -$712.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$1.41M 10-Q · filed 2025-08-12 | ||
| 2024-03-31 | -$699.00K 10-Q · filed 2025-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |